Natixis Advisors LLC Acquires New Holdings in Krystal Biotech, Inc. $KRYS

Natixis Advisors LLC acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,682 shares of the company’s stock, valued at approximately $2,880,000.

Other large investors have also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board grew its stake in Krystal Biotech by 15.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock valued at $17,729,000 after acquiring an additional 13,743 shares during the last quarter. SG Americas Securities LLC grew its stake in Krystal Biotech by 469.9% in the 4th quarter. SG Americas Securities LLC now owns 18,909 shares of the company’s stock valued at $4,662,000 after acquiring an additional 15,591 shares during the last quarter. William Blair Investment Management LLC grew its stake in Krystal Biotech by 63.9% in the 3rd quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock valued at $26,356,000 after acquiring an additional 58,203 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after purchasing an additional 39,000 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth about $1,450,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $309.75 on Wednesday. Krystal Biotech, Inc. has a 12-month low of $127.99 and a 12-month high of $319.48. The stock has a market capitalization of $9.13 billion, a P/E ratio of 41.41 and a beta of 0.53. The firm’s 50-day moving average is $284.68 and its two-hundred day moving average is $266.01.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million for the quarter, compared to analysts’ expectations of $112.11 million. As a group, analysts forecast that Krystal Biotech, Inc. will post 7.83 EPS for the current year.

Insider Activity at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KRYS. Evercore reaffirmed an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Citigroup raised their price target on shares of Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Chardan Capital raised their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Wall Street Zen raised shares of Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Ten research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.